. Author manuscript; available in PMC: 2019 Jan 1.

Published in final edited form as: Adv Protein Chem Struct Biol. 2017 Oct 6;111:1–59. doi: 10.1016/bs.apcsb.2017.08.003

Table 2.

Some of the Protein–Protein Interaction Inhibitors That Are in the Clinical Trial

Drug Name	Proprietary	Clinical Trial Stage	Indications	Website URL^a
BRD4 inhibitors
I-BET762 (GSK525762)	GSK	Phase II	Solid tumor	https://clinicaltrials.gov/ct2/show/NCT01587703
CPI-0610	Constellation Pharmaceutical, Cambridge, MA	Phase I	Lymphoma	https://clinicaltrials.gov/ct2/show/NCT01949883?term=CPI-0610&rank=2
Ten-010	Hoffmann-La Roche	Phase I	Acute myeloid leukemia	https://clinicaltrials.gov/ct2/show/NCT02308761?term=Ten-010&rank=1
OTX015 (MK-8628)	OncoEthix	Phase I	Cancer	https://clinicaltrials.gov/ct2/show/NCT01713582?term=OTX015&rank=2
BRD3 inhibitors
RVX-208	Resverlogix Corp	Phase II	Diabetes, atherosclerosis	https://clinicaltrials.gov/ct2/show/NCT01728467?term=RVX-208&rank=1
IAP inhibitors
LCL161	Novartis	Phase I	Advanced solid tumors	https://clinicaltrials.gov/ct2/show/NCT01098838?term=LCLl61&rank=5
GDC-0917/ CUDC-427	Genentech	Phase I	Solid cancer	https://clinicaltrials.gov/ct2/show/NCT01226277?term=GDC-0917&rank=l
GDC-0152 (RG7419)	Genentech	Phase I	Solid cancer	https://clinicaltrials.gov/ct2/show/NCT00977067?term=GDC-0152&rank=l
Bivalent inhibitors-SMAC mimetics
Birinapant (TL-32711)	TetraLogic Pharmaceuticals	Phase II	Cancer	https://clinicaltrials.gov/ct2/show/NCT01188499?term=Birinapant&rank=5

Date accessed May 17, 2017.